Luspatercept (new indication: beta-thalassemia, treatment of non-transfusion-dependent anemia)

Subject:

• Active Substance: Luspatercept
• Name: Reblozyl®
• Therapeutic area: Beta-thalassemia
• Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

• Start: 01.04.2023
• Final decision by G-BA: 21.09.2023

Final decision:

• Indication for a minor additional benefit